Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16218403 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL2151852 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL820340 | 0.83 | — | — | |
| SCHEMBL21925348 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL3133315 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL3515946 | 0.74 | — | — | |
| SCHEMBL7119977 | 0.74 | ALDH1A1 (0.33) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL2689613 | 0.73 | — | — | |
| SCHEMBL17715106 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL1029388 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2083623-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | ALDH1A1 4808/4885MAPK1 1500/4885TDP1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.